A combination of non-pharmacological and pharmacological treatment modalities is needed for optimal management of rheumatism. NSAIDs are now used extensively by patients with OA, who quite frequently also have one or more comorbidities. Paracetamol (acetaminophen) is the first oral analgesic to try. When this is not effective, we have the option of NSAID. Opioids as an alternative in those patients who are unresponsive to
A combination of non-pharmacological and pharmacological treatment modalities is needed for optimal management of rheumatism. NSAIDs are now used extensively by patients with OA, who quite frequently also have one or more comorbidities. Paracetamol (acetaminophen) is the first oral analgesic to try. When this is not effective, we have the option of NSAID. Opioids as an alternative in those patients who are unresponsive to
Copyright:
Attribution Non-Commercial (BY-NC)
Available Formats
Download as DOCX, PDF, TXT or read online from Scribd
A combination of non-pharmacological and pharmacological treatment modalities is needed for optimal management of rheumatism. NSAIDs are now used extensively by patients with OA, who quite frequently also have one or more comorbidities. Paracetamol (acetaminophen) is the first oral analgesic to try. When this is not effective, we have the option of NSAID. Opioids as an alternative in those patients who are unresponsive to
Copyright:
Attribution Non-Commercial (BY-NC)
Available Formats
Download as DOCX, PDF, TXT or read online from Scribd
Our primary aim in treating someone with any form of
arthritis is to stop the progression of the disease and to
help the patient to live as active and pain free a life as possible. Medical professionals have a range of treatments to offer people with arthritis or other forms of rheumatism. n the treatment of RA and SpA, major progress has been made in the last decade and NSADs are now used less in these patients. However, the number of patients with OA is increasing and NSADs are now used extensively by these (often elderly) patients, who quite frequently also have one or more comorbidities. As the European League Against Rheumatism (EULAR) guidelines on the treatment of OA clearly state, a combination of non-pharmacological and pharmacological treatment modalities is needed for optimal management [6]. Our first port of call is lifestyle changes with exercise and weight loss where appropriate, in addition to other non-pharmacological options including physiotherapy, education and coping programmes. The effect sizes (ESs) of these interventions may be limited (ES often in the range of 0.20) and partly due to placebo effects [7]. Where these need to be supplemented, there is a range of pharmacological treatments from local glucocorticoid injections to topical creams as well as oral pain relief [6, 8]. Paracetamol (acetaminophen) is the first oral analgesic to try. When this is not effective, we have the option of NSADs, with opioids as an alternative in those patients who are unresponsive to NSADs or intolerant of them [6]. The ESs of these NSADs are moderate (ES50.50) and they are preferred by many patients. t is the decision about when to use NSADswith the benefit of efficacy and the risks for some patientsthat is the focus of this supplement.
Tujuan utama kami dalam mengobati seseorang dengan segala bentuk arthritis adalah untuk menghentikan perkembangan penyakit dan untuk membantu pasien untuk hidup sebagai aktiI dan nyeri hidup bebas sebagai mungkin. ProIesional medis memiliki berbagai perawatan untuk menawarkan orang dengan radang sendi atau bentuk lain dari rematik. Dalam pengobatan RA dan SpA, kemajuan besar telah dibuat dalam dekade terakhir dan NSAID sekarang yang digunakan kurang pada pasien ini. Namun, jumlah pasien dengan OA meningkat dan NSAID sekarang digunakan ekstensiI oleh (sering lansia) pasien, yang cukup sering juga memiliki satu atau lebih komorbiditas. Sebagai Liga Eropa Melawan Rematik (EULAR) pedoman pada pengobatan OA jelas menyatakan, kombinasi pengobatan non-Iarmakologis dan Iarmakologis modalitas yang dibutuhkan untuk pengelolaan yang optimal |6|. Kami persinggahan pertama adalah perubahan gaya hidup dengan olahraga dan berat badan dimana tepat, di samping yang lain non-Iarmakologis pilihan, termasuk Iisioterapi, pendidikan dan program penanggulangan. EIek ukuran (ESS) dari intervensi ini mungkin terbatas (ES sering di kisaran 0,20) dan sebagian karena eIek plasebo |7|. Dimana ini perlu ditambah, ada berbagai Iarmakologis perawatan dari glukokortikoid lokal suntikan untuk krim topikal serta sebagai penghilang rasa sakit lisan |6, 8|. Parasetamol (asetaminoIen) merupakan analgesik oral pertama untuk mencoba. Bila ini tidak eIektiI, kita memiliki pilihan NSAID, dengan opioid sebagai alternatiI pada pasien yang tidak responsiI terhadap NSAID atau tidak toleran dari mereka |6|. ESS ini NSAID yang moderat (ES50.50) dan mereka lebih disukai oleh banyak pasien. Ini adalah keputusan tentang kapan harus menggunakan NSAID- dengan manIaat kemanjuran dan risiko untuk beberapa pasien-yang merupakan Iokus dari suplemen.
Professor Lanas examines new data on the increase in numbers of lower G events and illustrates how serious lower G complications can be. He considers how this fits into the context of assessing G risk in the entire G tract and looks at a new end-point for establishing whether our arthritis patients are experiencing lower G events. This may enable assessment of G health without sophisticated techniques such as balloon endoscopy. There is a dearth of studies with lower G events as their primary end-point to aid with this difficult issue and it is hoped that the outcome of the celecoxib or diclofenac and omeprazole for gastrointestinal safety in high. gastrointestinal risk patients with arthritis (CONDOR) study will add valuable evidence to enable improved patient outcomes.
ProIesor Lanas memeriksa data baru pada peningkatan jumlah peristiwa GI rendah dan menggambarkan seberapa serius GI rendah dapat komplikasi. Ia menganggap bagaimana cocok dalam konteks menilai risiko GI GI di seluruh saluran dan terlihat pada end-point baru untuk mendirikan apakah pasien arthritis kita mengalami GI rendah peristiwa. Hal ini dapat memungkinkan penilaian kesehatan GI tanpa canggih teknik seperti balon endoskopi. Ada kelangkaan studi dengan peristiwa GI rendah sebagai mereka titik akhir primer untuk membantu dengan masalah ini sulit dan itu adalah berharap bahwa hasil dari celecoxib atau dikloIenak dan omeprazole untuk keselamatan pencernaan tinggi
Acknowledgements Medical writing assistance was provided by Just:: Health PR Ltd, with financial support from Pfizer nc. The author was fully involved in all stages of the preparation of the manuscript, which was based on a round table conference under the chairmanship of Professor Lanas and the author. A medical writer assisted with searches of the literature and collation of data and supported the author in the drafting of the text. Ucapan Terima Kasih Bantuan menulis medis disediakan oleh Sama:: Kesehatan PR Ltd, dengan dukungan keuangan dari PIizer Inc Penulis sepenuhnya terlibat dalam semua tahap persiapan naskah, yang didasarkan pada sebuah konIerensi meja bundar di bawah pimpinan ProIesor dan Lanas penulis. Seorang penulis medis dibantu dengan pencarian literatur dan pengumpulan data dan mendukung penulis dalam penyusunan teks.
Supplement: This paper forms a part of the supplement entitled 'Balancing gastrointestinal benefit_risk in individuals who are prescribed NSADs for arthritis'. This supplement was supported by an unrestricted grant from Pfizer nc. Disclosure statement: J.W.J.B. is an advisor to Pfizer and has received honoraria as a speaker from Pfizer and MSD. Johannes W. J. Bijlsma1 1Department of Rheumatology and Clinical mmunology, University Medical Center Utrecht, Utrecht, The Netherlands Accepted 29 January 2010 Correspondence to: Johannes W. J. Bijlsma, Department of Rheumatology and Clinical mmunology, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands. E-mail: J.W.J.Bijlsma@umcutrecht.nl References 1 Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Org 2003;81:646_56. 2 European Opinion Research Group, EEG. Health, food, alcohol, and safety. Special Eurobarometer 186, Wave 59.0, Brussels, 2003. 3 WHO. The burden of musculoskeletal diseases at the start of the new millennium. Report of a WHO Scientific Group, Geneva, Switzerland, 2003, Technical Reports Series 919. Geneva: WHO, 2003. 4 Sprangers MA, de Regt E, Andries F et al. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol 2000;53:895_907. 5 TNS Health Care and Arthritis Care. Arthritis care survey. London: Arthritis Care, 2003. 6 Jordan KM, Arden NK, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for nternational Clinical Studies ncluding Therapeutic Trials (ESCST). Ann Rheum Dis 2003;62:1145_55. 7 Bijlsma JW, Welsing PM. The art of medicine in treating osteoarthritis: will please. Ann Rheum Dis 2008;67: 1653_5. 8 NCE clinical guideline 59. Osteoarthritis: the care and management of osteoarthritis in adults. http:// guidance.nice.org.uk/CG59/Guidance/pdf/English (March 2010, date last accessed). ii2 www.rheumatology.oxfordjournals.org Editorial Downloaded from rheumatology.oxfordjournals.org by guest on October 5, 2011
Tambahan: Tulisan ini merupakan bagian dari suplemen berjudul "Menyeimbangkan manIaat pencernaan? risiko dalam individu yang diresepkan NSAID untuk artritis '. Ini suplemen ini didukung oleh hibah tak terbatas dari PIizer Inc Pengungkapan pernyataan: J.W.J.B. adalah seorang penasihat untuk PIizer dan telah menerima honor sebagai pembicara dari PIizer dan MSD. Johannes W. J. Bijlsma 1 1Department oI Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Belanda Diterima 29 Januari 2010 Korespondensi untuk: Johannes WJ Bijlsma, Departemen Pra dan Clinical Immunology, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, Belanda. E-mail: J. W. J. Bijlsma umcutrecht.nl ReIerensi 1 WoolI AD, PIleger B. Beban muskuloskeletal utama kondisi. Bull Kesehatan Dunia Org 2003; 81:646 56?. 2 Opini Eropa Research Group, EEIG. Kesehatan, makanan, alkohol, dan keamanan. Khusus Eurobarometer 186, Gelombang 59,0, Brussels, 2003. 3 WHO. Beban penyakit muskuloskeletal pada awal milenium baru. Laporan WHO Kelompok Ilmiah, Jenewa, Swiss, 2003, Seri Laporan Teknis 919. Jenewa: WHO, 2003. 4 Sprangers MA, de Regt E, Andries F et al. Kronis yang kondisi yang berhubungan dengan kualitas lebih baik atau lebih buruk kehidupan? J Clin Epidemiol 2000; 53:895 907?. 5 TNS Kesehatan dan Arthritis Care. Arthritis perawatan survei. Jakarta: Arthritis Care, 2003. 6 Yordania KM, Arden NK, Doherty M et al. EULAR Rekomendasi 2003: suatu pendekatan berbasis bukti pengelolaan osteoartritis lutut: laporan Tugas Angkatan Komite Tetap Internasional Klinis Termasuk Studi Ujian Terapi (ESCISIT). Ann Rheum Dis 2003; 62:1145 55?. 7 Bijlsma JW, Welsing AM. Seni kedokteran dalam mengobati osteoartritis: Aku akan menyenangkan. Ann Rheum Dis 2008; 67: 1653? 5. 8 pedoman klinis NICE 59. Osteoarthritis: perawatan dan pengelolaan osteoartritis pada orang dewasa. http:// guidance.nice.org.uk/CG59/Guidance/pdI/E nglish (Maret 2010, tanggal terakhir diakses). ii2 www.rheumatology.oxIordjournals.org Tajuk rencana Download dari rheumatology.oxIordjournals.org oleh tamu pada 5 Oktober 2011